中国实用内科杂志2024，Vol.44Issue(1)：42-48,7.DOI:10.19538/j.nk2024010108
BTK抑制剂联合基础化疗治疗初诊双表达弥漫性大B细胞淋巴瘤5例临床分析
Clinical analysis of BTK inhibitors combined with basic chemotherapy in newly diagnosed double expression diffused large B cell lymphoma
摘要
Abstract
Objective To explore the clinical effect of BTK inhibitor combined with basic chemotherapy on newly diagnosed double-expressing diffuse large B-cell lymphoma(DLBCL).Methods Five cases of newly diagnosed MYC and BCL2 double-expressing DLBCL patients admitted to Nanjing First Hospital from November 2020 to March 2022 were retrospectively collected as research subjects.The patient's medical history is collected,and routine examinations,as well as PET-CT,bone marrow cell morphology,immunophenotyping,chromosomal detection and histological morphology,immunohistochemical examination,FISH and other specialized examinations are carried out.Results Five patients with MYC and BCL2 double-expressing DLBCL were initially diagnosed,of which 2 were high-grade B-cell lymphoma with not otherwise specified(HGBL,NOS),2 were CD5-positive double-expressing DLBCL patients.5 patients were given BTK-based combined chemotherapy,After three course of treatment,4 patients achieved CR,1 patient died after two course of treatment with central relapse,4 patients completed 6 courses of combination therapy and 2 courses of consolidation therapy,1 patient received autologous hematopoietic stem cell transplantation,all patients received intrathecal injection to prevent central invasion during treatment.As of October 2023,the median follow-up time was 31 months,and all 4 patients were in complete remission.Conclusion DLBCL patients with double expression of MYC and BCL2 were treated with BTK inhibitor combined with basic chemotherapy has a good effect and the safety is high,but the sample size needs to be expanded for further exploration in the later stage.关键词
弥漫性大B细胞淋巴瘤/双表达/BTK抑制剂Key words
diffuse large B-cell lymphoma/double-expressing/BTK inhibitor分类
医药卫生引用本文复制引用
杨丹,李凤,杨斐斐,赵有财,徐燕丽,张学忠,张秀群..BTK抑制剂联合基础化疗治疗初诊双表达弥漫性大B细胞淋巴瘤5例临床分析[J].中国实用内科杂志,2024,44(1):42-48,7.基金项目
南京市卫生科技发展项目(YKK19082) （YKK19082）
